Mitsubishi Tanabe Launches Take Over Bid For Generics Maker Choseido Pharmaceutical
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma announced May 7 it will acquire over 50 percent stake of Tokushima-based generic drugmaker Choseido Pharmaceutical. The move is believed to strengthen Mitsubishi Tanabe's position in the generics market, generic product lineup and allows Choseido to utilize Mitsubishi Tanabe's marketing and distribution channels. Mitsubishi Tanabe is in ongoing conversations with Choseido about acquiring additional shares. (Click here for more - Japanese language
You may also be interested in...
Developed by Japan’s national research institute, the supercomputer has been tasked with characterizing the SARS-CoV-2 virus, identifying therapeutic molecules, modeling infection spread and socio-economic impact.
Companies including Dr Reddy’s will consider investing in new API units if the Indian government tweaks its incentive scheme to permit exports of surplus production. Other suggested changes to the $1.3bn stimulus, aimed at enhancing the country's medicines security, include extending incentives to brownfield expansions and removing restrictions on a change in product mix.
The Global Generics & Biosimilars Awards 2020 will take place on 3 November as a digital event, with a newly-extended entry deadline date of 14 August.